Exploration of biological connotation of pathogenesis of non-alcoholic fatty liver disease due to liver depression and spleen deficiency based on liver-bile acid-intestinal microbiota Axis

HUANG Can; SHEN Yao-cun; LIU Shen-fan; ZHU Jie; WANG Zhi-bin

doi:10.16025/j.1674-1307.2023.05.023

您当前的位置：

首页 >

文章列表页 >

Exploration of biological connotation of pathogenesis of non-alcoholic fatty liver disease due to liver depression and spleen deficiency based on liver-bile acid-intestinal microbiota Axis

更新时间：2023-06-25

- Exploration of biological connotation of pathogenesis of non-alcoholic fatty liver disease due to liver depression and spleen deficiency based on liver-bile acid-intestinal microbiota Axis
- Beijing Journal of Traditional Chinese Medicine Vol. 42, Issue 5, Pages: 551-555(2023)
- 作者机构：
  
  1.北京中医药大学第二临床医学院，北京 100078
  2.北京中医药大学东方医院脾胃肝胆科，北京 100078
- 作者简介：
- 基金信息：
- DOI：10.16025/j.1674-1307.2023.05.023
  CLC：
扫描看全文
黄灿，沈垚村，刘深梵，等.基于“肝-胆汁酸-肠道菌群轴”论非酒精性脂肪性肝病肝郁脾虚病机的生物学内涵［J］.北京中医药，2023，42（5）：551-555.

HUANG Can,SHEN Yao-cun,LIU Shen-fan,et al.Exploration of biological connotation of pathogenesis of non-alcoholic fatty liver disease due to liver depression and spleen deficiency based on liver-bile acid-intestinal microbiota Axis[J]. Beijing Journal of Traditional Chinese Medicine,2023,42(05):551-555.
黄灿，沈垚村，刘深梵，等.基于“肝-胆汁酸-肠道菌群轴”论非酒精性脂肪性肝病肝郁脾虚病机的生物学内涵［J］.北京中医药，2023，42（5）：551-555. DOI： 10.16025/j.1674-1307.2023.05.023.

HUANG Can,SHEN Yao-cun,LIU Shen-fan,et al.Exploration of biological connotation of pathogenesis of non-alcoholic fatty liver disease due to liver depression and spleen deficiency based on liver-bile acid-intestinal microbiota Axis[J]. Beijing Journal of Traditional Chinese Medicine,2023,42(05):551-555. DOI： 10.16025/j.1674-1307.2023.05.023.

摘要

肝-胆汁酸-肠道菌群轴与非酒精性脂肪性肝病（NAFLD）的发生发展密切相关。中医学理论与临床研究发现“肝郁脾虚”是贯穿NAFLD始末的核心病机。结合西医学及分子生物学文献得知，肠道菌群失调与中医“脾虚”密切相关，胆汁酸代谢异常为“肝郁”的微观体现，肠道菌群与胆汁酸互相作用的失衡与中医“肝虚脾虚”病机相契合。从肝-胆汁酸-肠道菌群轴失调的角度探讨NAFLD肝郁脾虚的的生物学内涵，可以为中医药防治NAFLD提供科学依据以及新的临床思路。

Abstract

关键词

非酒精性脂肪性肝病胆汁酸肠道菌群肝郁脾虚

Keywords

references

非酒精性脂肪性肝病防治指南(2018更新版)[J].传染病信息,2018,31(5):393-402,420.

赵瀚东,杨帆,詹丽.非酒精性脂肪性肝病发病机制研究进展[J].解放军医学院学报,2022,43(3):366-371.

刘勤,牛春燕.由“二次打击”到“多重打击”:发病机制的演变带给非酒精性脂肪性肝病的治疗启示[J].世界华人消化杂志,2019,27(19):1171-1178.

侯康,李苏艳,宋丹琳,等.胆汁酸与肠道菌群在肠道疾病中的研究进展[J].胃肠病学和肝病学杂志,2021,30(12):1416-1420.

FORLAN0 R,SIVAKUMAR M,MULLISH BH,et al.Gut Microbiota-A future therapeutic target for people with non-alcoholic fatty liver disease: A systematic review[J].Int J Mol Sci,2022,23(15):8307.

KAUSHAL K,AGARWAL S,SHARMA S,et al.Demonstration of gut-barrier dysfunction in early stages of non-alcoholic fatty liver disease: A proof-of-concept study[J].J Clin Exp Hepatol,2022,12(4):1102-1113.

LI X,ZHAO W,XIAO M,et al.Penthorum Chinense pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice[J].J Ethnopharmacol,2022,294:115333.

JIAO N,BAKER SS,NUGENT CA,et al.Gut microbiome may contribute to insulin resistance and systemic inflammation in obese rodents: a meta-analysis[J].Physiol Genomics,2018,50(4):244-254.

NIMER N,CHOUCAIR I,WANG Z,et al.Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression[J].Metabolism,2021,116:154457.

PURI P,DAITA K,JOYCE A,et al.The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids[J].Hepatology,2018,67(2):534-548.

SHIN DJ,WANG L.Bile acid-activated receptors:a review on FXR and other nuclear receptors[J].Handb Exp Pharmacol,2019,256:51-72.

QIAO P,JIA Y,MA A,et al.Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice[J].Front Pharmacol,2022,13:934136.

HU YB,LIU XY,ZHAN W.Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis[J].Drug Des Devel Ther,2018,12:2213-2221.

YU X,HAO M,LIU Y,et al.Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy[J].Eur J Pharmacol,2019,864:172715.

KUHRE RE,WEWER ALBRECHTSEN NJ,LARSEN O,et al.Bile acids are important direct and indirect regulators of the secretion of appetite-and metabolism-regulating hormones from the gut and pancreas[J].Mol Metab,2018,11:84-95.

AIBILLOS A,DE GOTTARDI A,RESCIGNO M.The gut-liver axis in liver disease: Pathophysiological basis for therapy[J].J Hepatol，2020，72(3):558-577.

SINGH TP,KADYAN S,DEVI H,et al.Gut microbiome as a therapeutic target for liver diseases[J].Life Sci,2023，322:121685.

LUO M,YAN J,WU L,et al.Probiotics alleviated nonalcoholic fatty liver disease in high-fat diet-fed rats via gut microbiota/FXR/FGF15 signaling pathway[J].J Immunol Res,2021:2264737.

SHAO J,GE T,TANG C,et al.Synergistic anti-inflammatory effect of gut microbiota and lithocholic acid on liver fibrosis[J].Inflamm Res,2022:10.1007/s00011-022-01629-4.

KURDI P,KAWANISHI K, IZUTANI K, et al.Mechanism of growth inhibition by free bile acids in lactobacilli and bifidobacteria[J].J Bacteriol,2006,188:1979-1986.

YAMAUCHI R,TAKEDATSU H,YOKOYAMA K,et al.Elobixibat,an ileal bile acid transporter inhibitor,ameliorates non-alcoholic steatohepatitis in mice[J].Hepatol Int,2021,15(2):392-404.

张声生，李军祥.非酒精性脂肪性肝病中医诊疗专家共识意见(2017)[J].临床肝胆病杂志，2017,33(12):2270-2274.

李志国,姜韩雪,焦云涛,叶永安.非酒精性脂肪性肝病中医证型分布的文献分析[J].中华中医药杂志,2017,32(10):4713-4715.

谢添弘,陈润花,毛堂友,等.李军祥教授治疗非酒精性脂肪性肝炎临床经验[J].中国中西医结合消化杂志,2018,26(8):698-700.

张鹤,白宇宁,刘绍能，等.现代医学视角下中医“脾主运化”探析[J].北京中医药,2022,41(2):179-181.

林璋.脾虚证候患者肠道微生物和宿主代谢表型的关联性研究[D].上海：上海交通大学,2018.

吴珊珊,李军祥,李文艳,等.非酒精性脂肪性肝炎肝郁脾虚证与湿热内蕴证患者肠道菌群结构特征[J].北京中医药,2019,38(11):1135-1138.

JASIRWAN COM,MURADI A,HASAN I,et al.Correlation of gut Firmicutes/Bacteroidetes ratio with fibrosis and steatosis stratified by body mass index in patients with non-alcoholic fatty liver disease[J].Biosci Microbiota Food Health,2021,40(1):50-58.

洪力.基于肠道菌群和短链脂肪酸研究参苓白术散防治非酒精性脂肪肝的作用机制[D].昆明：云南中医药大学,2021.

GOLUBEVA JA,SHEPTULINA AF,YAFAROVA AA,et al.Reduced quality of life in patients with non-alcoholic fatty liver disease may be associated with depression and fatigue[J].Healthcare(Basel),2022,10(9):1699.

宋美芳.从胆汁酸-TGR5-GLP-1通路探讨抑郁模型大鼠糖代谢异常及逍遥散的作用机理[D].北京：北京中医药大学,2019.

吴菲,向华,阳丽.柴胡疏肝散加味干预妊娠期肝内胆汁淤积症临床疗效分析[J].中医药导报,2016,22(8):83-85.

李杰.小柴胡汤加减方对胆道术后脂餐饮食下血清中胆汁酸影响的临床研究[D].南京：南京中医药大学，2016.

刘凯利,张强,李军辉,等.柴胡人参药对通过调控胆汁酸代谢防治非酒精性脂肪肝的研究[J].中华中医药学刊,2022,40(3):101-106,267.

黄腊平,陈焰.基于Fibroscan技术的柴胡疏肝散对非酒精性脂肪肝患者临床疗效分析[J].清远职业技术学院学报,2020,13(2):35-38.

李丹.柴胡疏肝散对非酒精性脂肪肝胰岛素抵抗大鼠的防治作用及机制研究[D].广州：广东药学院,2014.

谢维宁,彭红兵,李烨,等.柴胡疏肝散对肝郁脾虚型非酒精性脂肪肝患者的临床疗效及肠道菌群的影响[J].中国实验方剂学杂志,2021,27(3):129-137.

周志强.基于肠道微生态研究逍遥散对非酒精性脂肪性肝病肝郁脾虚证的干预机制[D].成都：成都中医药大学,2020.

陈斌,徐嘉蔚,彭杰,等.基于逍遥散及其拆方研究“肝病实脾法”对肝纤维化大鼠肠道菌群的影响[J].临床肝胆病杂志,2016,32(4):657-662.

李辰浩,张玉蓉,赵微,等.“肝胆相表里”理论在非酒精性脂肪肝病中的运用概况[J].中国民族民间医药,2021,30(6):73-76.

孙枚,董坚,陈培峰,等.温胆汤加减治疗非酒精性脂肪肝病临床疗效及对患者血清炎性因子和免疫功能的影响[J].四川中医,2020,38(2):108-111.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Exploring the treatment of allergic rhinitis with WANG Le-ting's experienced ten acupoints as the main regulating gastrointestinal therapy

Research progress in pharmacological activity and pharmacokinetics of Ajuga

Effect of hot Chinese herbal bag on Shenque (CV8) point on diarrhea-predominant irritable bowel syndrome with Yang deficiency and intestinal flora

Discussion on the treatment of andrology diseases from the spleen and stomach based on intestinal flora

Clinical effect of Jiawei Hegan Decoction on functional constipation of liver depression and spleen deficiency pattern and its influence on serum intestinal neurotransmitters

Related Author

No data

Related Institution

首都医科大学附属北京中医医院

北京中医药大学东方医院

中国中医科学院广安门医院南区脾胃科

北京裕和中西医结合康复医院中医内科

北京中医药大学深圳医院中医男科

⁰